OBJECTIVE: @entity1211 ( @entity1211 ) is associated with almost 300,000 @entity204 per year in the United States. Novel oral anticoagulants (NOACs) offer an alternative to @entity1229 -based therapy without monitoring requirements and with fewer drug and food interactions. @entity14242 , a direct Xa inhibitor, is approved by the Food and Drug Administration (FDA), based upon results of the Hokusai- @entity1211 Phase 3 trial. The trial demonstrated that @entity14242 administered once daily after initial treatment with heparin was non-inferior in reducing the risk of @entity1211 recurrence and caused significantly less major and clinically relevant non-major (CRNM) bleeding compared to @entity1229 . The objective of this study was to evaluate the cost-effectiveness of @entity14242 versus @entity1229 for the treatment of adults with @entity1211 . METHODS: A cost-effectiveness model was developed using @entity1 -level data from the Hokusai- @entity1211 trial, clinical event costs from real-world databases, and drug acquisition costs for @entity1229 of  0.36 and @entity14242 of  9.24 per tablet. RESULTS: From a U.S. health-care delivery system perspective, the incremental cost-effectiveness ratio (ICER) was  22,057 per quality adjusted life year (QALY) gained. Probabilistic sensitivity analysis showed that @entity14242 had an ICER < 50,000 per QALY gained relative to @entity1229 in 67% of model simulations. The result was robust to variation in key model parameters including the cost and disutility of @entity1229 monitoring. CONCLUSION: Despite its higher drug acquisition cost, @entity14242 is a cost-effective alternative to @entity1229 for the treatment of @entity1211 .

Cost-effectiveness of @entity14242 for the treatment of @entity1211 based on the Hokusai- XXXX study.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity14242 :: ('MESH:C552171', 'Chemical') :: ['edoxaban', 'Edoxaban'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['Venous thromboembolism', 'VTE'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity1211 :: (MESH:D054556,Disease) :: ['VTE']
